Christian Francisco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christian Francisco has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Edsel Maurice Salvaña
Institute of Molecular Biology and Biotechnology, National Institutes of Health, University of the Philippines, Manila, Philippines
3 shared publications Angelo Dela Tonga
2 shared publicationsMarissa Alejandria
Division of Infectious Diseases, Philippine General Hospital, Manila, Philippines
2 shared publications- Brian Schwem
National Institutes of Health, University of the Philippines Manila, Manila, Philippines
1 shared publication Bryan Santiago
1 shared publicationChristine Penalosa
Division of Infectious Diseases, Philippine General Hospital, Manila, Philippines
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in IJID Regions
- Vol. 21
Clinical and molecular profile of Klebsiella pneumoniae bloodstream infections in a national referral hospital in the Philippines
- 15 October 2026
- Published by Elsevier in IJID Regions
- Vol. 21
Open AccessClinical and molecular profile of Klebsiella pneumoniae bloodstream infections in a national referral hospital in the Philippines
- Open Access
- 4 July 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 936-943
HIV‐1 Subtype Shift in the Philippines is Associated With High Transmitted Drug Resistance, High Viral Loads, and Fast Immunologic Decline
- 4 July 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 936-943
Open AccessHIV‐1 Subtype Shift in the Philippines is Associated With High Transmitted Drug Resistance, High Viral Loads, and Fast Immunologic Decline
- Open Access
- 1 May 2022
- Published by Journal of the ASEAN Federation of Endocrine Societies (JAFES) in Journal of the ASEAN Federation of Endocrine Societies
- Vol. 37 (1) , 1-9
Metabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis
Objectives. People living with HIV (PLHIV) are susceptible to develop dyslipidemia and hyperglycemia. This study aims to determine the prevalence of these metabolic derangements among Filipino PLHIV. Methodology. We reviewed 635 medical records in a treatment hub in Manila, Philippines from January 2004 to July 2016. Logistic regression analysis was done to determine factors associated with dyslipidemia and hyperglycemia pre and post-ART. Results. Among 635 PLHIV, 97.3% were males with mean age of 30 years and median CD4 count of 207 cells/mm(3). Pre-ART, prevalence of dyslipidemia was 65.4% and hyperglycemia was 10.4%. Risk factors for dyslipidemia include hyperglycemia (AOR 3.8, p 0.001) and >320 days delay in ART initiation from HIV confirmation (AOR 1.5, p 0.032), while dyslipidemia was associated with hyperglycemia (AOR 3.1, p 0.001). Post-ART, prevalence of dyslipidemia was 48.6% and hyperglycemia was 15.6%. Risk factors for post-ART dyslipidemia include being WHO stage 4 (AOR 2.1, p 0.021), hyperglycemia (AOR 16.1, p36 months ART duration (AOR 8.7, p<0.001) and efavirenz-based ART (AOR 2.8, p30 years (AOR 2.1, p 0.004), being overweight (AOR 1.8, p 0.023), dyslipidemia (AOR 17.8, p<0.001) and zidovudine-based ART (AOR 1.4, p 0.051). Conclusion. Dyslipidemia and hyperglycemia prevalence was high in Filipino PLHIV. Traditional, HIV and treatment related factors contributed to its development. Intensive monitoring and initiation of appropriate treatment is recommended.
- 1 May 2022
- Published by Journal of the ASEAN Federation of Endocrine Societies (JAFES) in Journal of the ASEAN Federation of Endocrine Societies
- Vol. 37 (1) , 1-9
Open AccessMetabolic Profile of People Living with HIV in a Treatment Hub in Manila, Philippines: A Pre- and Post-Antiretroviral Analysis
Objectives. People living with HIV (PLHIV) are susceptible to develop dyslipidemia and hyperglycemia. This study aims to determine the prevalence of these metabolic derangements among Filipino PLHIV. Methodology. We reviewed 635 medical records in a treatment hub in Manila, Philippines from January 2004 to July 2016. Logistic regression analysis was done to determine factors associated with dyslipidemia and hyperglycemia pre and post-ART. Results. Among 635 PLHIV, 97.3% were males with mean age of 30 years and median CD4 count of 207 cells/mm(3). Pre-ART, prevalence of dyslipidemia was 65.4% and hyperglycemia was 10.4%. Risk factors for dyslipidemia include hyperglycemia (AOR 3.8, p 0.001) and >320 days delay in ART initiation from HIV confirmation (AOR 1.5, p 0.032), while dyslipidemia was associated with hyperglycemia (AOR 3.1, p 0.001). Post-ART, prevalence of dyslipidemia was 48.6% and hyperglycemia was 15.6%. Risk factors for post-ART dyslipidemia include being WHO stage 4 (AOR 2.1, p 0.021), hyperglycemia (AOR 16.1, p36 months ART duration (AOR 8.7, p<0.001) and efavirenz-based ART (AOR 2.8, p30 years (AOR 2.1, p 0.004), being overweight (AOR 1.8, p 0.023), dyslipidemia (AOR 17.8, p<0.001) and zidovudine-based ART (AOR 1.4, p 0.051). Conclusion. Dyslipidemia and hyperglycemia prevalence was high in Filipino PLHIV. Traditional, HIV and treatment related factors contributed to its development. Intensive monitoring and initiation of appropriate treatment is recommended.
- Open Access
- 30 August 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (8) , e230628
Multidrug-resistant tuberculosis (MDR-TB) and multidrug-resistant HIV (MDR-HIV) syndemic: challenges in resource limited setting
Tuberculosis (TB) is common among persons living with HIV. This public health concern is aggravated by infection with multidrug-resistant organisms and adverse effects of polypharmacy. There are few published cases of multidrug-resistant tuberculosis (MDR-TB) in multidrug-resistant HIV (MDR-HIV) infected patients. We report a case of a 29-year-old Filipino man with HIV on zidovudine (AZT)-containing antiretroviral therapy (ART) but was eventually shifted to tenofovir due to anaemia. He presented with left flank tenderness, which was found to be due to an MDR-TB psoas abscess, and for which second-line anti-TB treatment was started. HIV genotyping showed MDR-HIV infection susceptible only to AZT, protease inhibitors and integrase inhibitors. Subsequently, he developed neck abscess that grew Mycobacterium avium complex and was treated with ethambutol and azithromycin. ART regimen was revised to AZT plus lamivudine and lopinavir/ritonavir. Erythropoietin was administered for recurrent AZT-induced anaemia. Both abscesses resolved and no recurrence of anaemia was noted.
- 30 August 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (8) , e230628
Open AccessMultidrug-resistant tuberculosis (MDR-TB) and multidrug-resistant HIV (MDR-HIV) syndemic: challenges in resource limited setting
Tuberculosis (TB) is common among persons living with HIV. This public health concern is aggravated by infection with multidrug-resistant organisms and adverse effects of polypharmacy. There are few published cases of multidrug-resistant tuberculosis (MDR-TB) in multidrug-resistant HIV (MDR-HIV) infected patients. We report a case of a 29-year-old Filipino man with HIV on zidovudine (AZT)-containing antiretroviral therapy (ART) but was eventually shifted to tenofovir due to anaemia. He presented with left flank tenderness, which was found to be due to an MDR-TB psoas abscess, and for which second-line anti-TB treatment was started. HIV genotyping showed MDR-HIV infection susceptible only to AZT, protease inhibitors and integrase inhibitors. Subsequently, he developed neck abscess that grew Mycobacterium avium complex and was treated with ethambutol and azithromycin. ART regimen was revised to AZT plus lamivudine and lopinavir/ritonavir. Erythropoietin was administered for recurrent AZT-induced anaemia. Both abscesses resolved and no recurrence of anaemia was noted.